BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26998681)

  • 1. Novel topical treatments for psoriasis: of interest or irrelevant?
    Garzorz N; Biedermann T
    Exp Dermatol; 2016 Jun; 25(6):426-7. PubMed ID: 26998681
    [No Abstract]   [Full Text] [Related]  

  • 2. The single-chain anti-TNF-α antibody DLX105 induces clinical and biomarker responses upon local administration in patients with chronic plaque-type psoriasis.
    Tsianakas A; Brunner PM; Ghoreschi K; Berger C; Loser K; Röcken M; Stingl G; Luger T; Jung T
    Exp Dermatol; 2016 Jun; 25(6):428-33. PubMed ID: 26738450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of patients with psoriasis during tumour necrosis factor (TNF)-α antagonist treatment using a novel interleukin-8 reporter cell line.
    Kimura Y; Shimada-Omori R; Takahashi T; Tsuchiyama K; Kusakari Y; Yamasaki K; Nishikawa R; Nishigori C; Aiba S
    Br J Dermatol; 2016 Nov; 175(5):979-987. PubMed ID: 27155194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Visfatin, Adiponectin, and Tumor Necrosis Factor Alpha (TNF-α) Levels in Patients with Psoriasis and their Correlation with Disease Severity.
    Sereflican B; Goksugur N; Bugdayci G; Polat M; Haydar Parlak A
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):13-9. PubMed ID: 27149125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Topical Use in Psoriasis Patients in the REFINE Study.
    Gooderham MJ; Poulin-Costello M; Shelton J; Bayan N; Papp KA
    J Cutan Med Surg; 2016; 20(2):106-12. PubMed ID: 26330052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
    Thaçi D; Ortonne JP; Chimenti S; Ghislain PD; Arenberger P; Kragballe K; Saurat JH; Khemis A; Sprøgel P; Esslinger HU; Unnebrink K; Kupper H
    Br J Dermatol; 2010 Aug; 163(2):402-11. PubMed ID: 20377585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of psoriasis vulgaris with peripheral blood eosinophilia, parallelling the psoriasis area and severity index (PASI) score.
    Sueki H; Nakada T; Iijima M
    Clin Exp Dermatol; 2004 Sep; 29(5):549-50. PubMed ID: 15347349
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma concentrations of IFN-gamma and TNF-alpha in psoriatic patients before and after local treatment with dithranol ointment.
    Chodorowska G
    J Eur Acad Dermatol Venereol; 1998 Mar; 10(2):147-51. PubMed ID: 9553912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis.
    Khandpur S; Sharma VK
    Clin Exp Dermatol; 2011 Aug; 36(6):613-6. PubMed ID: 21507036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
    Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
    Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B.
    Serwin AB; Wasowicz W; Chodynicka B
    Nutrition; 2006 Sep; 22(9):860-4. PubMed ID: 16829029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principal determinants of the length of remission of psoriasis vulgaris after topical, NB-UVB, and PUVA therapy: a follow-up study.
    Coimbra S; Oliveira H; Belo L; Figueiredo A; Rocha-Pereira P; Santos-Silva A
    Am J Clin Dermatol; 2013 Feb; 14(1):49-53. PubMed ID: 23329079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial.
    Yao DN; Lu CJ; Wen ZH; Yan YH; Xuan ML; Li XY; Li G; He ZH; Xie XL; Deng JW; Guo XF; Ou AH
    Trials; 2016 Mar; 17(1):140. PubMed ID: 26983642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.